Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-3135
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJossen, Valentin-
dc.contributor.authorvan den Bos, Christian-
dc.contributor.authorEibl-Schindler, Regine-
dc.contributor.authorEibl, Dieter-
dc.date.accessioned2019-07-25T13:39:16Z-
dc.date.available2019-07-25T13:39:16Z-
dc.date.issued2018-
dc.identifier.issn0175-7598de_CH
dc.identifier.issn1432-0614de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/17743-
dc.description.abstractHuman mesenchymal stem cell (hMSC)-based therapies are of increasing interest in the field of regenerative medicine. As economic considerations have shown, allogeneic therapy seems to be the most cost-effective method. Standardized procedures based on instrumented single-use bioreactors have been shown to provide billion of cells with consistent product quality and to be superior to traditional expansions in planar cultivation systems. Furthermore, under consideration of the complex nature and requirements of allogeneic hMSC-therapeutics, a new equipment for downstream processing (DSP) was successfully evaluated. This mini-review summarizes both the current state of the hMSC production process and the challenges which have to be taken into account when efficiently producing hMSCs for the clinical scale. Special emphasis is placed on the upstream processing (USP) and DSP operations which cover expansion, harvesting, detachment, separation, washing and concentration steps, and the regulatory demands.de_CH
dc.language.isoende_CH
dc.publisherSpringerde_CH
dc.relation.ispartofApplied Microbiology and Biotechnologyde_CH
dc.rightshttp://creativecommons.org/licenses/by/4.0/de_CH
dc.subjectAdvanced therapeutic medicinal productde_CH
dc.subjectAllogeneicde_CH
dc.subjectGood manufacturing practicede_CH
dc.subjectHuman mesenchymal stem cellde_CH
dc.subjectMicrocarrierde_CH
dc.subjectSingle-use devicede_CH
dc.subjectBioreactorde_CH
dc.subjectCell culture techniquede_CH
dc.subjectMesenchymal stem cellde_CH
dc.subjectBiomedical technology assessmentde_CH
dc.subjectCell- and tissue-based therapyde_CH
dc.subject.ddc660.6: Biotechnologiede_CH
dc.titleManufacturing human mesenchymal stem cells at clinical scale : process and regulatory challengesde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementLife Sciences und Facility Managementde_CH
zhaw.organisationalunitInstitut für Chemie und Biotechnologie (ICBT)de_CH
dc.identifier.doi10.21256/zhaw-3135-
dc.identifier.doi10.1007/s00253-018-8912-xde_CH
dc.identifier.pmid29564526de_CH
zhaw.funding.euNode_CH
zhaw.issue9de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end3994de_CH
zhaw.pages.start3981de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume102de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.author.additionalNode_CH
Appears in Collections:Publikationen Life Sciences und Facility Management

Files in This Item:
File Description SizeFormat 
Jossen2018_Article_ManufacturingHumanMesenchymal.pdf1.34 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.